Pancreatic Neoplasms clinical trials at UCSF
24 in progress, 12 open to eligible people
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
open to eligible people ages 18 years and up
This phase II trial studies how well ceralasertib, am Ataxia telangiectasia and Rad3-related (ATR) kinase inhibitor, works alone or in combination with olaparib or durvalumab in treating participants with renal cell carcinoma (RCC), urothelial…
San Francisco, California
Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
open to eligible people ages 18 years and up
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard(s) of care (SOC) treatment.
San Francisco, California and other locations
Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
open to eligible people ages 18 years and up
This study will assess the safety and efficacy of avutometinib (VS-6766) and defactinib in combination with gemcitabine and nab-paclitaxel in patients with Pancreatic Ductal Adenocarcinoma (PDAC) who have been previously untreated.
San Francisco, California and other locations
Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
open to eligible people ages 18 years and up
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a …
San Francisco, California and other locations
RYZ101 Compared with SOC in Pts W Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
open to eligible people ages 18 years and up
This study aims to determine the safety, pharmacokinetics (PK) and recommended Phase 3 dose (RP3D) of RYZ101 in Part 1, and the safety, efficacy, and PK of RYZ101 compared with investigator-selected standard of care (SoC) therapy in Part 2 in…
San Francisco, California and other locations
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
open to eligible people ages 12 months to 30 years
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with…
San Francisco, California and other locations
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
open to eligible people ages 18 years and up
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery (removable/resectable). Chemotherapy…
San Francisco, California and other locations
PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
open to eligible people ages 18 years and up
This phase II/III trial compares the effect of the 3-drug chemotherapy combination of nab-paclitaxel, gemcitabine, plus cisplatin versus the 2-drug chemotherapy combination of nab-paclitaxel plus gemcitabine for the treatment of patients with…
San Francisco, California and other locations
Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
open to eligible people ages up to 17 years
This clinical trial collects blood, saliva, urine, or stool samples to help identify possible genetic mutations that may increase a person's chance at developing pancreatic cancer. Finding genetic markers among pediatric patients with acute…
Oakland, California and other locations
Pancreatic Cancer Early Detection Consortium
open to eligible people ages 18-90
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with…
San Francisco, California and other locations
Pancreatic Cancer Screening
open to eligible people ages 18 years and up
This study investigates how often abnormal findings from routine magnetic resonance imaging occur in people with genetic mutations in BReast CAncer gene. (BRCA), ataxia telangiectasia mutated gene (ATM), or PALB2 screened for pancreatic cancer. This …
San Francisco, California
UCSF PANC Cyst Registry
open to eligible people ages 18 years and up
Pancreatic cysts are found incidentally on 15-50% of CT and MRIs for all indications and their prevalence is increasing. Many of these cysts may be precursors to pancreatic cancer, and thus pose a substantial risk, however, the vast majority are…
San Francisco, California
9-ING-41 in Patients with Advanced Cancers
Sorry, in progress, not accepting new patients
GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic…
San Francisco, California and other locations
TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Sorry, in progress, not accepting new patients
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, …
San Francisco, California and other locations
Cediranib in Combination With Olaparib in Advanced Solid Tumors
Sorry, in progress, not accepting new patients
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable), including breast…
San Francisco, California and other locations
MGC028 in Participants With Advanced Solid Tumors
Sorry, not currently recruiting here
The goal of this clinical trial is to characterize the safety, tolerability, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) or maximum administered dose of MGC028 (if no MTD is defined). The study will enroll adult participants…
San Francisco, California and other locations
PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Sorry, in progress, not accepting new patients
This study will test the safety of a drug called PF-08046049/SGN-BB228 in participants with melanoma and other solid tumors that are hard to treat or have spread through the body. It will also study the side effects of this drug. A side effect is…
San Francisco, California and other locations
Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Sorry, in progress, not accepting new patients
This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to …
San Francisco, California and other locations
Claudin18.2 CAR-T (CT041) in Patients with Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers
Sorry, in progress, not accepting new patients
A Phase 1b/2, open label, multi-center, clinical study of Chimeric Antigen Receptor T Cells (CAR-T) targeting claudin18.2 in patients with advanced gastric, pancreatic or other specified digestive system cancers
San Francisco, California and other locations
Comparing Two Methods to Follow Patients With Pancreatic Cysts
Sorry, in progress, not accepting new patients
The purpose of this study is to compare the two approaches for monitoring pancreatic cysts. The study doctors want to compare more frequent monitoring vs less frequent monitoring in order to learn which monitoring method leads to better outcome for…
San Francisco, California and other locations
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Sorry, in progress, not accepting new patients
This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620…
San Francisco, California and other locations
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
Sorry, in progress, not accepting new patients
This randomized phase II trial studies how well pazopanib hydrochloride works in treating patients with carcinoid tumors that are growing, spreading, or getting worse. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of…
San Francisco, California and other locations
Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
Sorry, in progress, not accepting new patients
This phase III trial studies cabozantinib to see how well it works compared with placebo in treating patients with neuroendocrine or carcinoid tumors that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of …
San Francisco, California and other locations
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
Sorry, in progress, not accepting new patients
This phase I trial studies the sides effects and best dose of hydroxychloroquine when given together with trametinib in treating patients with pancreatic cancer that has spread to nearby tissue, lymph nodes or other places in the body and cannot be…
San Francisco, California and other locations
Our lead scientists for Pancreatic Neoplasms research studies include Pamela N Munster, MD Margaret Tempero, MD Rahul Aggarwal Paige M Bracci, PhD, MPH, MS Andrew Ko Kimberly S Kirkwood, MD Julia Carnevale Kieuhoa T. Vo.
Last updated: